Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.44 |
| ▸ | PELI1 | Q96FA3 | 1/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28111651 | 0.85 | ERN1 (0.47) | ERN1PELI1ESR1ESR2ALDH5A1 | |
| SCHEMBL29076111 | 0.78 | ERN1 (0.50) | ERN1PELI1ESR1ESR2ALDH5A1 | |
| SCHEMBL8011498 | 0.78 | HSD17B10 (0.50) | ERN1PELI1ESR1ESR2ALDH5A1 | |
| SCHEMBL6640732 | 0.78 | ERN1 (0.70) | ERN1PELI1 | |
| SCHEMBL20873238 | 0.75 | ALOX5 (0.56) | PELI1TYRESR1ESR2 | |
| SCHEMBL10595101 | 0.75 | ALOX5 (0.56) | PELI1TYRESR1ESR2 | |
| SCHEMBL17625725 | 0.75 | BACE1 (0.60) | PELI1TYRESR1ESR2 | |
| SCHEMBL17660183 | 0.75 | ERN1 (0.52) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL9721340 | 0.74 | ERN1 (0.46) | ERN1PELI1ESR1ESR2ALDH5A1 | |
| Hydroquinone SCHEMBL11562733 | 0.74 | ERN1 (0.59) | ERN1TRIM24TRIM33ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412327-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG Biomedical Institute (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | ERN1 446/4885PELI1 1219/4885TRIM24 1983/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | ERN1 446/4885PELI1 1219/4885TRIM24 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.